Studies have shown that about 10% of HIV infected patients can develop non-Hodgkin's lymphoma; The incidence rate is 60 times higher than that of non-HIV-infected people. Aids patients with long infection period are at greater risk. Most non-Hodgkin's lymphomas are histologically highly malignant progressive β -cell lymphomas, including immunoblastic lymphoma and diffuse small unclassified (Birket or Birket) lymphoma. Non-Hodgkin's lymphoma associated with HIV infection is often diffuse in diagnosis. It can involve extranodal tissues, such as bone marrow, digestive tract, and sites invaded by Hodgkin's lymphoma unrelated to HIV infection, such as central nervous system and body cavities (pleural cavity, pericardium and abdominal cavity). The pathogenesis of non-Hodgkin's lymphoma associated with HIV infection may vary according to the histological subtype or invasion site of the disease. For example, EB virus, which causes B cell cloning and expansion, can be detected from most Birket-like lymphomas and almost all central nervous system lymphomas related to HIV infection, but it is rarely found in other immunoblastic lymphomas. Similarly, C-myc oncogene rearrangement and p53 tumor suppressor gene mutation are typical manifestations of diffuse small undifferentiated lymphoma, but they are rare in immunoblastic lymphoma. Signs and diagnostic AIDS: Patients with non-Hodgkin's lymphoma often have one or more lymph nodes that swell rapidly, or a lump forms outside the lymph nodes or systemic symptoms (b) such as weight loss (10% of the body weight), night sweats or fever. Abnormal peripheral blood lymphocytes or unexpected pancytopenia suggest bone marrow invasion, which can be diagnosed by biopsy. When the chest, abdomen and other parts are involved, CT examination is of great significance to determine the stage and scope of the disease and formulate the treatment plan. Because of the high incidence of central nervous system invasion, cerebrospinal fluid examination should be listed as a basic examination item in diagnosis. The related factors of poor prognosis include poor functional status, bone marrow invasion, conditional infection history and highly malignant tissue subtypes. Progressive non-Hodgkin's lymphoma should be treated with systemic multidrug chemotherapy combined with antiretroviral drugs. Prophylactic antibiotics and hematopoietic growth factors are used for treatment. It is difficult for patients with advanced AIDS to tolerate chemotherapy, because chemotherapy will cause extreme bone marrow suppression. A modified dosage regimen can be used for these patients. The history of conditional infection can often judge the tolerance to treatment. The combination therapy of antiretroviral, antibiotics and antifungal drugs can reduce tolerance, but non-Hodgkin's lymphoma with AIDS patients without obvious conditional infection history. After intensive combined chemotherapy and supportive treatment, it is possible to cure. It is effective to use additional radiotherapy for giant lymphoma or to control the pain and bleeding caused by tumor. (Editor: Wu Liangzhen) For more questions about malignant lymphoma, please click → Share: More.